Founded in 2018 and evolving through strategic mergers, Opus Genetics focuses on developing gene therapies for inherited retinal diseases (IRDs) with a specialized portfolio of seven AAV-based programs. Financially, the company bears significant operating losses driven by pipeline progression but maintains robust liquidity with a current ratio above 6. Its lead candidate, OPGx-LCA5, benefits from expedited regulatory pathways while facing the inherent developmental risks typical of early-stage biotech. Limited equity financing capacity and ongoing patent litigation underscore notable operational risks. Observers should monitor clinical milestones, regulatory developments, and manufacturing scale-up as indicators of future progress.